TNG-908 is under clinical development by Tango Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TNG-908’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TNG-908 overview

TNG-908 is under development for the treatment of MTAP-deleted cancers like cholangiocarcinoma, mesothelioma, squamous and non squamous non-small cell lung cancer, bladder cancer, diffuse large b-cell lymphoma, malignant peripheral nerve sheath tumor (MPNST)glioblastoma multiforme, colon cancer. It is administered through oral route. It acts by targeting the protein arginine methyltransferase 5 (PRMT5) enzyme.

Tango Therapeutics overview

Tango Therapeutics, formerly Tango Therapeutics, is a biotechnology company that discovers and develops novel drug targets for the treatment of cancer. The company is investigating TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) against methylthioadenosine phosphorylase (MTAP) deleted cancers. It is also developing drugs for BRCA1-mutant breast, ovarian and prostate cancer, lung cancer, and solid tumors. Tango Therapeutics utilizes CRISPR (clustered regularly interspaced short palindromic repeats) based functional genomics target discovery platform to detect novel synthetic lethal targets for loss or deactivation of multiple tumor suppressor genes. It works in collaboration with Gilead Sciences to discover, develop, and commercialize cancer therapies. Tango Therapeutics is headquartered in Boston, Massachusetts, the US.

For a complete picture of TNG-908’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.